HemCon Medical Technologies (HemCon), a developer of advanced wound medical products, has signed an exclusive licensing agreement with Zeria Pharmaceuticals (Zeria). Through the partnership, Zeria will market, distribute, and sell HemCon’s line of wound and oral care dressings throughout Japan.
Zeria’s partnership with HemCon will allow them to strategically expand their product offering and market reach in the wound care, surgery, oral care, and patient safety markets.
Sachiaki Ibe, president and CEO of Zeria, said: “Zeria will be establishing a separate division to specifically manage the HemCon product line as a new pillar in Zeria’s business.”
John Morgan, CEO of HemCon, said: “HemCon is proud to be partnering with Zeria, one of the most well-balanced operating companies in the Japanese health care arena, to bring our advanced wound care products to the Japanese market.
“The partnership will also give HemCon the opportunity to break into the Asian market, which has not been the company’s focus until now, and represents a significant opportunity to help provide unique solutions for patient safety and wound care in Japan.”
HemCon’s product offerings include a full line of hemostatic dressings with antibacterial properties. The technology, originally developed for use on the battlefield to control severe hemorrhaging, is used in acute care settings worldwide for bleeding control, wound management, and infection prevention.
HemCon line also includes OTC line of hemostatic products and oral wound care dressing for oral surgery and periodontal procedures.
Zeria’s portfolio includes hemostatic surgical compounds, which the HemCon products will augment. Zeria also operates in the gastroenterology (GI) field and markets products in dermatology and cardiovascular disease. The company also markets a range of consumer healthcare products and medications.